BackgroundCervical cancer is the second-most-common cause of malignancies in women worldwide, and the oncogenic activity of the human papilloma virus types (HPV) E7 protein has a crucial role in anogenital tumors. In this study, we have designed a therapeutic vaccine based on chitosan nanodelivery systems to deliver HPV-16 E7 DNA vaccine, considered as a tumor specific antigen for immunotherapy of HPV-associated cervical cancer. We have developed a Nano-chitosan (NCS) as a carrier system for intramuscular administration using a recombinant DNA vaccine expressing HPV-16 E7 (NCS-DNA E7 vaccine). NCS were characterized in vitro for their gene transfection ability.ResultsThe transfection of CS-pEGFP NPs was efficient in CHO cells and the expression of green fluorescent proteins was well observed. In addition, NCS-DNA E7 vaccine induced the strongest E7-specific CD8+ T cell and interferon γ responses in C57BL/6 mice. Mice vaccinated with NCS-DNA E7 vaccine were able to generate potent protective and therapeutic antitumor effects against challenge with E7-expressing tumor cell line, TC-1.ConclusionsThe strong therapeutic effect induced by the Chitosan-based nanodelivery suggest that nanoparticles may be an efficient carrier to improve the immunogenicity of DNA vaccination upon intramuscular administration and the platform could be further exploited as a potential cancer vaccine candidate in humans.

Chitosan nanoparticles (CS NPs) were prepared as a carrier for Human papillomavirus type 16 HPV-16) E7 gene and their gene transfection ability were evaluated in vitro. The plasmid expressing green fluorescent protein (pEGFP) was used as a reporter gene. Gel electrophoresis demonstrated full binding of CS NPs with the pDNA. The transfection of CS-pEGFP NPs was efficient in CHO cells and the expression of green fluorescent proteins was well observed. The expression of E7 proteins was confirmed under SDS-PAGE and western blot analysis. As a conclusion CS NPs may serve as an effective nonviral carrier for delivery of nucleotides into eukaryotic cells.

Background:GB Virus C is a blood-borne virus and a member of Flaviviridae, like hepatitis C that is distributed globally and puts hemodialysis patients at high risk of developing liver disease. The clinical significance of GBV-C in this population remains unclear.Objectives:The current study aimed to evaluate GBV-C infection among hemodialysis patients.Patients and Methods:Totally, 149 patients receiving hemodialysis were included in the study. The detection of GBV-C sequences in plasma was done by the nested Reverse transcription polymerase chain reaction (RT-PCR) using specific primers selected from highly conserved regions of 5' UTR of GBV-C and antibodies to the envelope protein of GBV-C (anti-E2 GBV-C antibody) were analyzed by also serological methods. In addition, Hepatitis B surface antigen (HBsAg), Hepatitis B core antibody (HBcAb) IgM, anti- Hepatitis C virus (HCV) and anti- hepatitis E virus (HEV) Ab was determined in patients who were GBV-C RNA and anti-E2 GBV-C antibody positive.Results:The total prevalence of GBV-C infection was 14.7% (95%CI: 0.09-0.21) among patients receiving hemodialysis. The rate of GBV-C viremia and anti-E2 antibody positivity were 6.04% and 10.73%, respectively. Among the subjects who were positive for GBV-C, 27.27% (95% CI: 0.02-0.09), 45.45% (95% CI: 0.03-0.11), 59.9% (95% CI: 0.06-0.16) and 0% (95% CI: 0.01-0.07) were positive for anti-HCV, anti-HBsAg, anti-HBc IgM and anti-(HEV) Ab, respectively. In addition, the rate of both anti-HBc IgM /anti-HCV/ HBsAg and anti-HBc IgM /anti-HCV positivity in GBV-C infected cases were 9.09%. The liver enzymes were normal in all of them. There was significant difference between GBV-C exposures with viral hepatitis co-infection, but there was no correlation between GBV-C exposure with gender, age, ethnicity, time on dialysis and history of blood transfusions. A relatively high frequency of positivity GBV-C-exposure among hemodialysis patients suggested that the transmission route for GBV-C may be nosocomial transmission, and via transfusions.Conclusions:The current study found a relatively high frequency of positivity GBV-C-exposure among the patients receiving hemodialysis in the area understudy. Nosocomial transmission seems to be the main route of GBV-C infection in the area.

No abstract

Background:Ophthalmic pterygium is a common benign lesion of unknown origin and the pathogenesis might be vision-threatening. This problem is often associated with exposure to solar light. Recent evidence suggests that potentially oncogenic viruses such as human papillomavirus and Epstein-Barr virus may be involved in the pathogenesis of pterygia. Expression of specific adenovirus genes such as E1A and E1B, which potentially have many functions, may contribute to their oncogenic activity as well as relevance to cellular immortalization.Objectives:For the first time, we aimed to investigate involvement of adenoviruses in pterygium formation.Patients and Methods:Fifty tissue specimens of pterygium from patients undergoing pterygium surgery (as cases), 50 conjunctival swab samples from the same patients and 10 conjunctival biopsy specimens from individuals without pterygium such as patients undergoing cataract surgery (as controls) were analyzed for evidence of adenovirus infection with polymerase chain reaction using specific primers chosen from the moderately conserved region of the hexon gene. Furthermore, β-globin primers were used to access the quality of extracted DNA. Data was analyzed using SPSS (version 16) software.Results:Of 50 patients, 20 were men and 30 women with mean age of 61.1 ± 16.9 years ranged between 22 and 85 years. All samples of pterygia had positive results for adenoviruses DNA with polymerase chain reaction, but none of the negative control groups displayed adenoviruses. The pterygium group and the control groups were β-globin positive. Direct sequencing of PCR products confirmed Adenovirus infection.Conclusions:Adenoviruses might act as a possible cause of pterygium formation and other factors could play a synergistic role in the development. However, further larger studies are required to confirm this hypothesis.

Background and Aims: Hepatitis E virus (HEV) infection is usually a self-limited viral disease that causes acute hepatitis and may progress to chronic hepatitis in immunosuppressed individuals. It seems that hemodialysis patients and HIV infected people are more exposed to HEV infection. The aim of this study was to evaluate the extent of HEV infection in hemodialysis and HIV infected patients in Iran using serological molecular methods. Materials and Methods: Serum and plasma samples were collected from 149 patients undergoing hemodialysis and also 102 proved HIV infected patients. Theses sera were used for detection of HEV total antibodies with Enzyme immunoassay and HEV RNA by Real Time PCR. Demographic and clinical data were obtained and analyzed by SPSS version 16. Results: HEV antibody for hemodialysis patients and HIV infected individuals were (4%) and (33.3%) respectively. No viremia was observed in both HIV and hemodialysis serum samples. There was no association between demographic and clinical data and HEV antibody positive people. Conclusions: This study showed some different results in comparison with other studies in Iran. These conflicting results showed differences between HEV infection in hemodialysis and HIV-infected patients in Iran.

No abstract

Background and Objectives: Red blood cell (RBC) transfusion is necessary for the prevention and treatment of a variety of life-threatening injuries and diseases. However, viral contamination of these products is a great threat to recipients. Screening donors for GB virus C by nucleic acid testing is not routinely implemented worldwide. The aim of the present study was to evaluate prevalence of GBV-C RNA in whole blood/red cell components. Methods: In this cross sectional pilot study, we collected 153 units of packed RBCs from blood banks of two public hospitals in Gorgan (northeast of Iran), between October and November 2014. The samples were screened for the presence of GBV-C RNA in plasma by nested RT-PCR using specific primers targeting highly conserved regions of 5' UTR of GBV-C. Data were analyzed using SPSS software (version 18). Results: Overall, 48 (31.37%) whole blood or red cell components were positive for GBV-C viremia. The GBV-C RNA was detected in 31/88 citrate phosphate dextrose-adenine 1 (CPDA1) RBC, 16/50 washed RBC and 1/13 reduced-leukocyte RBC. However, whole blood CPDA1 was negative for GBV-C viremia. Direct sequencing of PCR products confirmed GBV-C contamination. Conclusions: Transmission of GBV-C infection was observed in blood products. Thus, efforts should be made to develop new strategies for assuring blood transfusion safety.